Related Experiment Video

Updated: Sep 30, 2026

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates
13:55

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates

Published on: January 27, 2019

Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives

M S Braga1, L Lauria-Pires, E R Argañaraz

  • 1Chagas' Disease Multidisciplinary Research Laboratory, University of Brasília, Federal District, Brazil.

Revista Do Instituto De Medicina Tropical De Sao Paulo
|July 11, 2000
PubMed

Insights

Treatment with nitroderivatives did not achieve parasitological cure in chronic Chagas' disease patients. Molecular methods showed persistent Trypanosoma cruzi DNA in both treated and untreated individuals, indicating limited treatment efficacy.

Area of Science:

  • Infectious Diseases
  • Molecular Biology
  • Parasitology

Background:

  • Chagas' disease, caused by Trypanosoma cruzi, is a chronic infection affecting millions.
  • Current treatments for chronic Chagas' disease have limitations in achieving parasitological cure.

Purpose of the Study:

  • To evaluate the parasitological cure of chronic Trypanosoma cruzi infections in humans treated with nitroderivatives.
  • To quantify Trypanosoma cruzi DNA in blood samples of treated and untreated patients using molecular methods.

Main Methods:

  • Study included 17 treated chronic Chagas' disease patients, 17 untreated patients, and 17 controls.
  • Polymerase Chain Reaction (PCR) assays with nested T. cruzi DNA primers were used to detect parasite DNA.
  • Competitive PCR quantified parasite load in blood (T. cruzi/ml).

Main Results:

  • T. cruzi DNA was detected in both untreated and treated chronic Chagas' disease patients.
  • Parasite loads were < 1 to 75 T. cruzi/ml in untreated and < 1 to 36 T. cruzi/ml in treated patients.
  • The difference in mean parasite load between treated and untreated groups was not statistically significant.

Conclusions:

  • Nitroderivatives do not appear to achieve parasitological cure in chronic Trypanosoma cruzi infections.
  • Further research is needed to define the role of nitrofuran and nitroimidazole compounds in treating chronic Chagas' disease.
  • Molecular monitoring is crucial for assessing treatment efficacy in Chagas' disease.

More Related Videos

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing &#946;-galactosidase08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies07:59

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies

Published on: May 31, 2024

Related Concept Videos

Toxoplasmosis01:28

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
Trichomoniasis01:18

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...